{"id":"NCT01058668","sponsor":"Forest Laboratories","briefTitle":"Safety and Efficacy of Cariprazine for Bipolar I Disorder","officialTitle":"A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2010-01-29","resultsPosted":"2017-04-12","lastUpdate":"2017-04-12"},"enrollment":497,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Mania","Bipolar I Disorder"],"interventions":[{"type":"DRUG","name":"Cariprazine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cariprazine (3-6 mg/day)","type":"EXPERIMENTAL"},{"label":"Cariprazine (6-12 mg/day)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar I disorder.","primaryOutcome":{"measure":"Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3","timeFrame":"Baseline, Week 3","effectByArm":[{"arm":"Placebo","deltaMin":-12.5,"sd":0.8},{"arm":"Cariprazine (3-6 mg/Day)","deltaMin":-18.6,"sd":0.8},{"arm":"Cariprazine (6-12 mg/Day)","deltaMin":-18.5,"sd":0.8}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":66,"countries":["United States","Croatia","Romania","Russia","Serbia","Ukraine"]},"refs":{"pmids":["31344528","29017067","25562205"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":161},"commonTop":["Akathisia","Headache","Insomnia","Nausea","Vomiting"]}}